Logo image of CNTB

CONNECT BIOPHARMA HOLDINGS L (CNTB) Stock Price, Quote, News and Overview

NASDAQ:CNTB - Nasdaq - US2075231017 - ADR - Currency: USD

0.8251  +0.01 (+0.62%)

After market: 0.8003 -0.02 (-3.01%)

CNTB Quote, Performance and Key Statistics

CONNECT BIOPHARMA HOLDINGS L

NASDAQ:CNTB (5/2/2025, 8:00:01 PM)

After market: 0.8003 -0.02 (-3.01%)

0.8251

+0.01 (+0.62%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.08
52 Week Low0.51
Market Cap45.59M
Shares55.25M
Float32.70M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)09-05 2025-09-05
IPO03-19 2021-03-19


CNTB short term performance overview.The bars show the price performance of CNTB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20

CNTB long term performance overview.The bars show the price performance of CNTB in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -10 -20 -30 -40

The current stock price of CNTB is 0.8251 USD. In the past month the price increased by 39.85%. In the past year, price decreased by -48.11%.

CONNECT BIOPHARMA HOLDINGS L / CNTB Daily stock chart

CNTB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.57B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.30B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About CNTB

Company Profile

CNTB logo image Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in San Diego, California and currently employs 62 full-time employees. The company went IPO on 2021-03-19. The company is building a pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. Its second product candidate, icanbelimod, is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). Icanbelimod is an orally available, small molecule modulator of S1P1 that is designed to reduce inflammation without killing T cells.

Company Info

CONNECT BIOPHARMA HOLDINGS L

3580 Carmel Mountain Road, Suite 200

San Diego CALIFORNIA 215400 US

CEO: William Pan

Employees: 81

CNTB Company Website

CNTB Investor Relations

Phone: 18587271040

CONNECT BIOPHARMA HOLDINGS L / CNTB FAQ

What is the stock price of CONNECT BIOPHARMA HOLDINGS L today?

The current stock price of CNTB is 0.8251 USD. The price increased by 0.62% in the last trading session.


What is the ticker symbol for CONNECT BIOPHARMA HOLDINGS L stock?

The exchange symbol of CONNECT BIOPHARMA HOLDINGS L is CNTB and it is listed on the Nasdaq exchange.


On which exchange is CNTB stock listed?

CNTB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CONNECT BIOPHARMA HOLDINGS L stock?

8 analysts have analysed CNTB and the average price target is 6.12 USD. This implies a price increase of 641.73% is expected in the next year compared to the current price of 0.8251. Check the CONNECT BIOPHARMA HOLDINGS L stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CONNECT BIOPHARMA HOLDINGS L worth?

CONNECT BIOPHARMA HOLDINGS L (CNTB) has a market capitalization of 45.59M USD. This makes CNTB a Nano Cap stock.


How many employees does CONNECT BIOPHARMA HOLDINGS L have?

CONNECT BIOPHARMA HOLDINGS L (CNTB) currently has 81 employees.


What are the support and resistance levels for CONNECT BIOPHARMA HOLDINGS L (CNTB) stock?

CONNECT BIOPHARMA HOLDINGS L (CNTB) has a support level at 0.82 and a resistance level at 0.84. Check the full technical report for a detailed analysis of CNTB support and resistance levels.


Is CONNECT BIOPHARMA HOLDINGS L (CNTB) expected to grow?

The Revenue of CONNECT BIOPHARMA HOLDINGS L (CNTB) is expected to decline by -100% in the next year. Check the estimates tab for more information on the CNTB EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CONNECT BIOPHARMA HOLDINGS L (CNTB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CONNECT BIOPHARMA HOLDINGS L (CNTB) stock pay dividends?

CNTB does not pay a dividend.


When does CONNECT BIOPHARMA HOLDINGS L (CNTB) report earnings?

CONNECT BIOPHARMA HOLDINGS L (CNTB) will report earnings on 2025-09-05.


What is the Price/Earnings (PE) ratio of CONNECT BIOPHARMA HOLDINGS L (CNTB)?

CONNECT BIOPHARMA HOLDINGS L (CNTB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.15).


What is the Short Interest ratio of CONNECT BIOPHARMA HOLDINGS L (CNTB) stock?

The outstanding short interest for CONNECT BIOPHARMA HOLDINGS L (CNTB) is 0.2% of its float. Check the ownership tab for more information on the CNTB short interest.


CNTB Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to CNTB. When comparing the yearly performance of all stocks, CNTB is a bad performer in the overall market: 85.81% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CNTB Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CNTB. While CNTB has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CNTB Financial Highlights

Over the last trailing twelve months CNTB reported a non-GAAP Earnings per Share(EPS) of -0.15. The EPS increased by 91.24% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -7.88%
ROE -8.66%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%74.9%
Sales Q2Q%N/A
EPS 1Y (TTM)91.24%
Revenue 1Y (TTM)N/A

CNTB Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to CNTB. The Buy consensus is the average rating of analysts ratings from 8 analysts.

For the next year, analysts expect an EPS growth of -359.19% and a revenue growth -100% for CNTB


Ownership
Inst Owners44.85%
Ins Owners0.03%
Short Float %0.2%
Short Ratio0.53
Analysts
Analysts85
Price Target6.12 (641.73%)
EPS Next Y-359.19%
Revenue Next Year-100%